Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Suspected TANSSI team mints 45 million tokens, just three weeks after the last large issuance

Suspected TANSSI team mints 45 million tokens, just three weeks after the last large issuance

ForesightNewsForesightNews2025/12/13 12:02
Show original

Foresight News reported that, according to Arkham monitoring, an address suspected to belong to the application chain infrastructure protocol TANSSI team has minted a total of 45 million new tokens (worth nearly $700,000) through multiple transactions. This comes only about three weeks after the last large-scale token issuance, during which the team minted and issued 23 million TANSSI tokens and subsequently sent a portion of the tokens to an exchange.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million

Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.

智通财经•2026/10/09 07:11

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08